Abstract:
:Tumor-associated macrophages (TAMs), representing most of the leukocyte population in solid tumors, demonstrate great phenotypic heterogeneity and diverse functional capabilities under the influence of the local tumor microenvironment. These anti-inflammatory and protumorigenic macrophages modulate the local microenvironment to facilitate tumor growth and metastasis. In this review, we examine the origin of TAMs and the complex regulatory networks within the tumor microenvironment that facilitate the polarization of TAMs toward a protumoral phenotype. More extensively, we evaluate the mechanisms by which TAMs mediate angiogenesis, metastasis, chemotherapeutic resistance and immune evasion. Lastly, we will highlight novel interventional strategies targeting TAMs in preclinical studies and in early clinical trials that have significant potential in improving efficacy of current chemotherapeutic and/or immunotherapeutic approaches.
journal_name
Immunotherapyjournal_title
Immunotherapyauthors
Petty AJ,Yang Ydoi
10.2217/imt-2016-0135subject
Has Abstractpub_date
2017-03-01 00:00:00pages
289-302issue
3eissn
1750-743Xissn
1750-7448journal_volume
9pub_type
杂志文章,评审相关文献
Immunotherapy文献大全abstract::γδ T cells are capable of recognizing tumor cells and exert potent cellular cytotoxicity against a large range of tumors, including colon cancer. However, tumors utilize numerous strategies to escape recognition or killing by patrolling γδ T cells, such a downregulation of NKG2D ligands, MICA/B and ULBPs. Therefore, t...
journal_title:Immunotherapy
pub_type: 杂志文章,评审
doi:10.2217/imt.14.59
更新日期:2014-01-01 00:00:00
abstract::HER2/neu is expressed in the majority of in situ breast cancers, but maintained in 20-30% of invasive breast cancer (IBC). During breast tumorigenesis, there is a progressive loss of anti-HER2 CD4(pos) Th1 (anti-HER2Th1) from benign to ductal carcinoma in situ, with almost complete loss in IBC. This anti-HER2Th1 respo...
journal_title:Immunotherapy
pub_type: 杂志文章,评审
doi:10.2217/imt-2016-0052
更新日期:2016-10-01 00:00:00
abstract::Over the last few years, extensive research has improved our understanding of tumor immunology and has enabled the development of novel treatments. The state of the art of immunotherapy in various types of malignancies was exhaustively discussed in the 'Immunotherapy Bridge' meeting, which was held in Naples on 4-5 De...
journal_title:Immunotherapy
pub_type: 杂志文章
doi:10.2217/imt-2020-0042
更新日期:2020-02-01 00:00:00
abstract:AIMS:A therapeutic vaccine based on monocyte-derived dendritic cells (MDDCs) has been shown to represent a promising strategy for the treatment of cancer and viral infections. Here, we characterized the MDDCs used as an immunogen in a clinical trial for an anti-HIV-1 therapeutic vaccine. PATIENTS & METHODS:Monocytes o...
journal_title:Immunotherapy
pub_type: 杂志文章
doi:10.2217/imt-2017-0165
更新日期:2018-08-01 00:00:00
abstract::Mycobacterium bovis bacille Calmette-Guerin (BCG) is one of the great success stories of immunotherapy as a treatment for superficial urothelial carcinoma of the bladder. Despite clinical effectiveness in over 50% of patients, the high incidence of local side effects and presence of nonresponders has led to efforts to...
journal_title:Immunotherapy
pub_type: 杂志文章,评审
doi:10.2217/1750743X.1.2.281
更新日期:2009-03-01 00:00:00
abstract::Histone deacetylase inhibitors possess a broad array of antitumor activities; however, their net impact on the evolving antitumor immune response is highly dependent on the inhibitors used and the histone deacetylases they target. Herein, we sequentially focus on each stage of the antitumor immune response - from dend...
journal_title:Immunotherapy
pub_type: 杂志文章,评审
doi:10.2217/imt-2017-0134
更新日期:2017-12-01 00:00:00
abstract::Although treatment options for castration-resistant prostate cancer (CRPC) have increased over the last decade, there remains a need for strategies that can provide durable disease control and long-term benefit. Recently, immunotherapy has emerged as a viable and attractive strategy for the treatment of CRPC. To date,...
journal_title:Immunotherapy
pub_type: 杂志文章,评审
doi:10.2217/imt.15.101
更新日期:2016-01-01 00:00:00
abstract::Epstein-Barr virus-associated lymphoproliferative diseases (EBV-LPD) after hematopoietic stem cell transplantation or solid-organ transplantation remain a serious and potentially life-threatening complication. In the last decade, outcomes for EBV-LPD have significantly improved. Key to this success was the development...
journal_title:Immunotherapy
pub_type: 杂志文章,评审
doi:10.2217/imt.10.43
更新日期:2010-09-01 00:00:00
abstract:AIM:Placenta specific 1 (PLAC1) is a protein rarely expressed in normal cells, except it is important for placental development, with a possible role in the establishment of the mother-fetus interface. The gene is also highly active in a wide variety of cancers and therefore, immunization with PLAC1 peptides could poss...
journal_title:Immunotherapy
pub_type: 杂志文章
doi:10.2217/imt-2017-0019
更新日期:2017-05-01 00:00:00
abstract::Waldenström macroglobulinemia (WM) is a lymphoproliferative lymphoma that is characterized by monoclonal immunoglobulin M (IgM) protein and bone marrow infiltration. Its incidence is rare and rarer still is its ability to transform to a B-cell lymphoma, particularly the aggressive diffuse large B-cell lymphoma, which ...
journal_title:Immunotherapy
pub_type: 杂志文章
doi:10.2217/imt-2017-0027
更新日期:2017-08-01 00:00:00
abstract::Non-coding RNAs (ncRNAs) are an abundant component of the human transcriptome. Their biological role, however, remains incompletely understood. Nevertheless, ncRNAs are highly associated with cancer development and progression due to their ability to modulate gene expression, protein translation and growth pathways. I...
journal_title:Immunotherapy
pub_type: 杂志文章
doi:10.2217/imt-2019-0204
更新日期:2020-05-01 00:00:00
abstract::There has been growing evidence that heat-shock protein (HSP) functions as an endogenous immunomodulator for innate and adaptive immune responses. Since HSPs inherently act as chaperones within cells, passive release (e.g., by cell necrosis) and active release (including release by secretion in the form of an exosome)...
journal_title:Immunotherapy
pub_type: 杂志文章,评审
doi:10.2217/imt.12.75
更新日期:2012-08-01 00:00:00
abstract::Progressive multifocal leukoencephalopathy (PML) is a rare and severe complication of natalizumab therapy in patients with multiple sclerosis and it may be accompanied by immune reconstitution inflammatory syndrome (IRIS). Here, we describe a case of abnormally severe IRIS, which occurred 2 months after natalizumab-as...
journal_title:Immunotherapy
pub_type: 杂志文章
doi:10.2217/imt.13.155
更新日期:2014-01-01 00:00:00
abstract::Sarcoidosis is a systemic disease with an incidence of 1 to 40 per 100 000 persons per year. It predominantly affects people in the age of 20 to 40 years old. Disease course varies from mild self-limiting to chronic debilitating and life-threatening disease. Since the cause of sarcoidosis is unknown, curative therapy ...
journal_title:Immunotherapy
pub_type: 杂志文章,评审
doi:10.2217/imt.14.65
更新日期:2014-01-01 00:00:00
abstract::Targeted immunotherapies represent a valid strategy for the treatment of metastatic castrate-resistant prostate cancer. A randomized, double-blind, Phase II clinical trial of PROSTVAC® demonstrated a statistically significant improvement in overall survival and a large, global, Phase III trial with overall survival as...
journal_title:Immunotherapy
pub_type: 杂志文章,评审
doi:10.2217/imt.13.176
更新日期:2014-01-01 00:00:00
abstract::In COVID-19, the inflammatory cytokine-release syndrome is associated with the progression of the disease. Itolizumab is a monoclonal antibody that recognizes human CD6 expressed in activated T cells. The antibody has shown to be safe and efficacious in the treatment of moderate to severe psoriasis. Its effect is asso...
journal_title:Immunotherapy
pub_type: 杂志文章
doi:10.2217/imt-2020-0235
更新日期:2021-03-01 00:00:00
abstract::Systemic lupus erythematosus is a systemic autoimmune disease characterized by the presence of myriad autoantibodies, some with pathogenic potential, and diverse clinical manifestations. Involvement of the kidney is a major cause of morbidity and mortality in human lupus patients and in murine models of the disease. I...
journal_title:Immunotherapy
pub_type: 杂志文章
doi:10.2217/imt.12.20
更新日期:2012-04-01 00:00:00
abstract::Aim: To investigate whether and how CD4+ T cells contribute to ILC2 activation during respiratory syncytial virus (RSV) infection. Methods: The methods of flow cytometry, quantitative PCR and ELISA were used in the present study. Results: Depletion of CD4+ T cells diminished the numbers of lung ILC2s as well as their ...
journal_title:Immunotherapy
pub_type: 杂志文章
doi:10.2217/imt-2019-0084
更新日期:2019-10-01 00:00:00
abstract::Background: The purpose of this study was to assess the effectiveness of immune checkpoint inhibitors (ICIs) in advanced urothelial carcinoma. Materials & methods: We selected seven cohorts of patients published in four clinical trials. The restricted mean survival time (RMST) was used to analyze survival curves, perf...
journal_title:Immunotherapy
pub_type: 杂志文章
doi:10.2217/imt-2020-0160
更新日期:2021-02-01 00:00:00
abstract::Background: Progress in immunotherapy (IT) has shifted treatment paradigms for multiple malignancies. In March 2019, the combination of nab-paclitaxel and atezolizumab was approved by the US FDA for patients with PD-L1 positive metastatic triple-negative breast cancer based on positive results of the Impassion130 tria...
journal_title:Immunotherapy
pub_type: 杂志文章
doi:10.2217/imt-2020-0202
更新日期:2020-12-01 00:00:00
abstract::Currently, limited data exist on the safety of pembrolizumab in patients with metastatic melanoma who have developed severe immune-related adverse events following treatment with ipilimumab. We report a 45-year-old male patient with BRAF-mutant metastatic melanoma who discontinued treatment with ipilimumab due to trea...
journal_title:Immunotherapy
pub_type: 杂志文章
doi:10.2217/imt-2015-0025
更新日期:2016-06-01 00:00:00
abstract::Evaluation of: Davila ML, Riviere I, Wang X et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci. Transl. Med. 6(224), 224ra25 (2014). Recently, chimeric antigen receptor (CAR) T-cell immunotherapy has entered clinical trials in patients with relapsed or refr...
journal_title:Immunotherapy
pub_type: 评论,杂志文章
doi:10.2217/imt.14.44
更新日期:2014-01-01 00:00:00
abstract::Activation of a patient's immune system offers an attractive approach to prevent and treat hepatocellular carcinoma (HCC). However, the antitumor efficacy of current HCC vaccines was weak owing to insufficient immune activation of targeting self/tumor antigens. We recently found that epitope-optimized α-fetoprotein ef...
journal_title:Immunotherapy
pub_type: 杂志文章,评审
doi:10.2217/imt.14.46
更新日期:2014-01-01 00:00:00
abstract::The complex homeostasis of tissues is coordinated by the cytokine network and imbalances in this network may result in chronic immune disorders. Key specific cytokines, such as TNF-alpha, IFN-alpha, IL-4 or VEGF have been demonstrated to be overproduced or abnormally released in the microenvironment of pathologic tiss...
journal_title:Immunotherapy
pub_type: 杂志文章,评审
doi:10.2217/imt.10.16
更新日期:2010-05-01 00:00:00
abstract:AIM:This study assessed the safety of Polyoxidonium® 6 mg lyophilisate for solution for injection in routine practice with a special focus on signs or symptoms of potential adverse renal effects. MATERIALS & METHODS:A local, multicenter, prospective, open-label, noninterventional, uncontrolled postauthorization safety...
journal_title:Immunotherapy
pub_type: 杂志文章,多中心研究
doi:10.2217/imt-2017-0116
更新日期:2018-02-01 00:00:00
abstract::Evaluation of: Pujol-Autonell I, Ampudia RM, Monge P et al. Immunotherapy with tolerogenic dendritic cells alone or in combination with rapamycin does not reverse diabetes in NOD mice. ISRN Endocrinol. doi:10.1155/2013/346987 (2013) (Epub ahead of print). Many reports confirm that dendritic cells (DCs) can prevent aut...
journal_title:Immunotherapy
pub_type: 评论,杂志文章
doi:10.2217/imt.13.50
更新日期:2013-06-01 00:00:00
abstract::Aim: Autologous hematopoietic stem cell transplantation (ASCT) is the standard-of-care curative treatment for relapsed or refractory diffuse large B-cell lymphoma (RR-DLBCL), but the relapse rate is usually high. Materials & methods: In this study, we treated 14 RR-DLBCL patients by combining ASCT and anti-CD19 chimer...
journal_title:Immunotherapy
pub_type: 杂志文章
doi:10.2217/imt-2020-0075
更新日期:2020-09-01 00:00:00
abstract::Background: Immunotherapy has revolutionized the treatment of cancer, but this has not come without a cost. Although immune checkpoint inhibitors are less toxic than conventional chemotherapy, they are associated with more frequent autoimmune side effects. Case presentation: We report a case of a patient with metastat...
journal_title:Immunotherapy
pub_type: 杂志文章
doi:10.2217/imt-2020-0053
更新日期:2020-06-01 00:00:00
abstract::In spite of the considerable successes that have been achieved in the treatment of chronic myeloid leukemia (CML), cure for the disease can only be obtained by the present means in a rather small minority of patients. During the past decade, considerable progress has been made in the understanding of the immunology of...
journal_title:Immunotherapy
pub_type: 杂志文章,评审
doi:10.2217/imt.10.2
更新日期:2010-03-01 00:00:00
abstract::Chronic rhinosinusitis with nasal polyposis (CRSwNP) imparts a significant healthcare challenge, resulting in diminished quality of life for patients and high costs with resource utilization for disease management. Understanding of CRSwNP pathophysiology has progressively evolved and the identification of various infl...
journal_title:Immunotherapy
pub_type: 杂志文章,评审
doi:10.2217/imt-2019-0191
更新日期:2020-02-01 00:00:00